Brain Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Brain Cancer, including details on symptoms, benign and malignant tumors, gliomas, treatment.

Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.

Liu R, Martuza RL, Rabkin SD

Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Charlestown, MA 02129, USA.

Delivery of viral vectors to tumors in the brain is a challenge, especially via systemic administration, which is key to targeting the invasive margins of malignant glioma and the multiple foci of metastatic disease. Like for other cancer therapeutics, the blood-brain barrier or even the blood-tumor barrier significantly limits delivery and efficacy. Blood-brain barrier disruption (BBBD) is one strategy for transiting the cerebrovasculature. G47Delta is a third-generation oncolytic replication-competent herpes simplex virus (HSV) vector, containing deletions of the gamma34.5 and alpha47 genes and an inactivating LacZ insertion in UL39 (ICP6). Intracarotid artery delivery of G47Delta after BBBD with 25% mannitol significantly extended the life of nude mice bearing intracerebral human MDA-MB-435 breast tumors, whereas, G47Delta injection contralateral to the tumor, in the absence of mannitol or mannitol alone had no effect on survival. G47Delta replication was extensive after BBBD, as visualized by X-gal staining. Staining of peripheral organs, lung and liver, was minimal and not altered by BBBD. This is the first demonstration of intracarotid arterial delivery of oncolytic HSV vectors and antitumor efficacy in a mouse model and opens the door to the use of mouse syngenic tumor models and transgenic/knockout animals.

Published 7 April 2005 in Gene Ther, 12(8): 647-54.
Full-text of this article is available online (may require subscription).

© 2004-2008 Brain Cancer Research Today. All Rights Reserved.